Skip to main content
News

Equ Healthcare Announces Its First AI Beta Program for GLP-1 Medication Management

Equ Healthcare announced its first AI beta program on March 10, 2025, with a first demonstration focused on GLP-1 medication management.

The Equ Healthcare logo mark, shared with the company’s March 10, 2025 announcement of its first AI beta program and GLP-1 medication-management demonstration. Credit: Image courtesy of Dr. Omar Costilla Reyes.
Dr. Costilla Reyes presents the first version of the Equ Healthcare platform at the MIT CSAIL Alliances Annual Meeting, April 29, 2025. Related photograph from Introducing the Equ Healthcare platform at the MIT CSAIL Alliances Annual Meeting 2025. Credit: Image courtesy of Dr. Omar Costilla Reyes.

First AI beta and GLP-1 demo

On March 10, 2025, Equ Healthcare announced its first AI beta program and invited people to experience a first demonstration of its solution. The demonstration focused on medication management for GLP-1 treatment, including Ozempic. Dr. Omar Costilla Reyes founded Equ Healthcare in April 2024 and leads it as founder and chief executive officer. The company describes its approach as integrating wearable, laboratory, lifestyle, behavioral, and contextual signals into explainable, personalized health intelligence.

What GLP-1 medication management involves

GLP-1 (glucagon-like peptide-1) medications imitate a gut hormone that helps regulate blood sugar and appetite. Ozempic is a brand of semaglutide, a once-weekly injection prescribed for type 2 diabetes, and medicines in this class are also used for weight management. Treatment usually starts at a low dose that is raised in steps, and people are asked to watch for side effects such as nausea. Dose timing, missed doses, symptoms, eating, and activity therefore need to be followed over many weeks, which is the kind of day-to-day management the demonstration addressed. When Dr. Costilla Reyes presented the first version of the platform at the MIT CSAIL Alliances Annual Meeting on April 29, 2025, the slide on screen was titled “Your Intelligent GLP-1 Medication Management Companion”; that talk has its own page.

Context and what followed

The beta followed Equ Healthcare’s introduction at New York TechWeek in June 2024, where Dr. Costilla Reyes described a mission of reducing medical costs and increasing access to care, and the company’s January 2025 entry into the MIT CSAIL Alliances member ecosystem. A beta program is the stage at which early users try a product and their experience guides its refinement, so the announcement invited early users to try the platform hands-on. In May 2026 the company said it was opening its beta to a wider audience as the solution continued to improve. Related pages cover the TechWeek launch and the company’s October 2025 collaboration announcement with Mayo Clinic.

Topics